Background illustration for clinical trials search

Paid Clinical Trials Ohio

Discover 3,048 paid clinical trials in Ohio. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.

Filter
1
FeaturedActive & Responsive

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

for
Moderately to Severely Active Ulcerative Colitis
Location: Providence RI, Lebanon NH, North Massapequa NY,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06588855

Phase3, Recruiting
FeaturedActive & Responsive

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

for
Geographic Atrophy
Location: Philadelphia PA, Baltimore MD, Durham NC, Lynchburg VA,
Sponsor: Genentech, Inc.

Sex: All

Age: 50+

Code: NCT05626114

Phase2, Recruiting
FeaturedActive & Responsive

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

for
Influenza
Location: Miami FL, Charleston SC, Smithfield PA,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 0 - 11

Code: NCT06094010

Phase3, Recruiting
FeaturedActive & Responsive

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

for
Juvenile Psoriatic Arthritis
Location: Valhalla NY, New York NY, Washington D.C. DC,
Sponsor: AbbVie

Sex: All

Age: 5 - 17

Code: NCT06100744

Phase3, Recruiting
FeaturedActive & Responsive

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for
Moderately to Severely Active Crohns Disease
Location: Boston MA, Providence RI, North Massapequa NY,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819878

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
FeaturedNew

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

for
Obesity, Overweight
Location: Morehead City NC, Newport News VA, New Bern NC,
Sponsor: AbbVie

Sex: All

Age: 18 - 70+

Code: NCT07752979

Phase2, Recruiting
Featured

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

for
Multiple Myeloma
Location: New York NY, Newark DE, Fairfax VA, Chapel Hill NC,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT05650632

Phase1, Recruiting
Featured

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

for
Mature B-Cell Non-Hodgkin Lymphoma
Location: Boston MA, New York NY, Baltimore MD, Cincinnati OH,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 0 - 30

Code: NCT05533775

Phase1, Phase2, Recruiting
Featured

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Location: Columbus OH, Rochester MN, Salt Lake City UT
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT05091424

Phase1, Recruiting
Featured

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

for
Huntington Disease
Location: Boston MA, Philadelphia PA, Pittsburgh PA, Columbus OH,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 25 - 65

Code: NCT06826612

Phase1, Phase2, Recruiting
Featured

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

for
Non Small Cell Lung Carcinoma
Location: Boston MA, Shirley NY, East Brunswick NJ, Easton PA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06772623

Phase1, Phase2, Recruiting
Featured

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

for
Metastatic Colorectal Cancer
Location: Boston MA, New Haven CT, Montreal, Fairfax VA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06820463

Phase2, Recruiting
Featured

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

for
Moderately to Severely Active Crohns Disease
Location: Providence RI, North Worcester MA, Lebanon NH,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 16 - 70+

Code: NCT06819891

Phase3, Recruiting
Featured

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

for
Non-Small Cell Lung Cancer
Location: New Haven CT, Westbury NY, The Bronx NY, Teaneck NJ,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06568939

Phase2, Recruiting
Featured

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, Lebanon NH, New York NY,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT04302025

Phase2, Recruiting
Featured

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

for
Juvenile Idiopathic Arthritis
Location: Valhalla NY, Washington D.C. DC, Cincinnati OH,
Sponsor: AbbVie

Sex: All

Age: 1 - 17

Code: NCT05609630

Phase3, Recruiting
Featured

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

for
Small Cell Lung Cancer
Location: Boston MA, Bethlehem PA, Fairfax VA, Winchester VA,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07365241

Phase3, Recruiting
Featured

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

for
Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Location: Philadelphia PA, Fairfax VA, Cleveland OH,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT07490301

Phase2, Phase3, Recruiting
Featured

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

for
Ovarian Cancer
Location: Scarborough ME, Worcester MA, Camden NJ,
Sponsor: AbbVie

Sex: Female

Age: 18+

Code: NCT07059845

Phase2, Recruiting
Featured

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

for
Multiple Myeloma
Location: New Haven CT, Washington D.C. DC, Winston-Salem NC,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT07555938

Phase3, Recruiting

Popular cities in Ohio

With a robust healthcare network, renowned medical research centers, and innovative treatments, Ohio is a leading destination for a wide range of clinical trials. Institutions such as the Cleveland Clinic, Ohio State University Wexner Medical Center, University Hospitals Cleveland Medical Center, and Nationwide Children’s Hospital are at the forefront of these studies.

Why choose Ohio for clinical trials?

Ohio offers distinct advantages in the clinical research landscape. The state's diverse population provides a wide range of participants, enhancing the accuracy and relevance of research outcomes. Ohio is also recognized for its strong research environment, with a focus on medical innovation and pioneering studies in various fields.

By choosing to participate in a clinical trial in Ohio, participants contribute to vital medical research while benefiting from a well-established clinical trial infrastructure supported by top-tier healthcare institutions. This ensures they receive cutting-edge care and support throughout the process.

Common conditions studied in Ohio

Local regulations and guidelines

Benefits of participating in clinical trials

How to enroll in a clinical trial in Ohio